China Pharma Holdings Inc (CPHI)vsUnited Therapeutics Corporation (UTHR)
CPHI
China Pharma Holdings Inc
$0.59
-6.19%
HEALTHCARE · Cap: $4.96M
UTHR
United Therapeutics Corporation
$541.60
+1.84%
HEALTHCARE · Cap: $23.74B
Smart Verdict
WallStSmart Research — data-driven comparison
United Therapeutics Corporation generates 72297% more annual revenue ($3.18B vs $4.40M). UTHR leads profitability with a 41.9% profit margin vs -83.2%. CPHI appears more attractively valued with a PEG of 0.16. UTHR earns a higher WallStSmart Score of 67/100 (B-).
CPHI
Hold47
out of 100
Grade: D+
UTHR
Strong Buy67
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for CPHI.
Margin of Safety
+62.9%
Fair Value
$1282.02
Current Price
$541.60
$740.42 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Growing faster than its price suggests
Reasonable price relative to book value
Keeps 42 of every $100 in revenue as profit
Strong operational efficiency at 45.0%
Safe zone — low bankruptcy risk
Earnings expanding 24.5% YoY
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -52.7% — below average capital efficiency
Negative free cash flow — burning cash
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : CPHI
The strongest argument for CPHI centers on PEG Ratio, Price/Book. Revenue growth of 10.9% demonstrates continued momentum. PEG of 0.16 suggests the stock is reasonably priced for its growth.
Bull Case : UTHR
The strongest argument for UTHR centers on Profit Margin, Operating Margin, Altman Z-Score. Profitability is solid with margins at 41.9% and operating margin at 45.0%.
Bear Case : CPHI
The primary concerns for CPHI are EPS Growth, Market Cap, Return on Equity.
Bear Case : UTHR
The primary concerns for UTHR are PEG Ratio.
Key Dynamics to Monitor
CPHI profiles as a turnaround stock while UTHR is a mature play — different risk/reward profiles.
CPHI carries more volatility with a beta of 1.04 — expect wider price swings.
CPHI is growing revenue faster at 10.9% — sustainability is the question.
UTHR generates stronger free cash flow (173M), providing more financial flexibility.
Bottom Line
UTHR scores higher overall (67/100 vs 47/100), backed by strong 41.9% margins. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
China Pharma Holdings Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · China
China Pharma Holdings, Inc. develops, manufactures and markets generic and branded pharmaceutical and biochemical products primarily for hospitals and private retailers in the People's Republic of China. The company is headquartered in Haikou, the People's Republic of China.
United Therapeutics Corporation
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
United Therapeutics Corporation, a biotechnology company, is dedicated to the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company is headquartered in Silver Spring, Maryland.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?